Articles published by Niagen Bioscience, Inc.

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

October 15, 2026

From Niagen Bioscience, Inc.

Via Business Wire

Tickers NAGE

Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes

September 21, 2026

From Niagen Bioscience, Inc.

Via Business Wire

Tickers NAGE

Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference

August 12, 2026

From Niagen Bioscience, Inc.

Via Business Wire

Tickers NAGE

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

August 04, 2026

From Niagen Bioscience, Inc.

Via Business Wire

Tickers NAGE

Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research

July 16, 2026

From Niagen Bioscience, Inc.

Via Business Wire

Tickers NAGE

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

August 06, 2025

From Niagen Bioscience, Inc.

Via Business Wire

Tickers NAGE

Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

February 09, 2026

From Niagen Bioscience, Inc.

Via Business Wire

Tickers NAGE

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.